

*10.12.2019*

**13:30 - 17:40**    **Type: Educational session**    **Room TBC**  
**Title: SITC-ESMO Immunotherapy Primer (LIMITED AVAILABILITY)**

13:30 - 14:00    **T-cell, B cell, and NK cell biology**

14:00 - 14:30    **DC-based immunology and antigen presentation**

14:30 - 14:40    **Break**

14:40 - 15:10    **Cytokines and small molecules**

15:10 - 15:40    **Tumour microenvironment and immune cell exhaustion**

15:40 - 16:10    **Coffee break**

16:10 - 16:40    **Adoptive cellular therapies and bispecifics**

16:40 - 17:10    **Biomarkers**

17:10 - 17:40    **Animal models for immunotherapy: Pros and cons**

11.12.2019

**09:00 - 10:30**    **Type: Educational session**    **Room A**  
**Title: Introduction to immunotherapy in cancer**  
Moderation: Pedro Romero, CH; John Haanen, NL

09:00 - 09:20    **Understanding the basics of immunotherapy**  
A. Furness, The Royal Marsden NHS Foundation Trust, London, GB

09:20 - 09:40    **Immunomodulation through immune-checkpoints**  
A. Curioni, University Hospital Zürich, Zurich, CH

09:40 - 10:00    **Cancer vaccines**  
B. Szabados, Barts Cancer Institute-Queen Mary University of London, London, GB

10:00 - 10:20    **Cell therapies against cancer**  
M. Donia, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

10:20 - 10:30    **General discussion / Q&A**

**12:15 - 13:15**    **Type: Industry Satellite Symposium**    **Room C**  
**Title: Industry Satellite Symposium 1**

**13:15 - 13:45**    **Type: Coffee break**    **Foyer**  
**Title: Welcome reception**

**13:45 - 14:00**    **Type: Educational session**    **Room A**  
**Title: Opening session**

**14:00 - 14:30**    **Type: Educational session**    **Foyer**  
**Title: Opening Keynote lecture - ESMO Award for Immuno-Oncology 2019**

**14:40 - 16:10** **Type: Educational session** **Room A**  
**Title: Adoptive cell therapy for precision targeting of cancer**  
Moderation: John Haanen, NL; Sine Reker Hadrup, DK

14:40 - 15:00 **Cell therapy with tumour infiltrating lymphocytes**  
P. Hwu, MD Anderson Cancer Center, Houston, US

15:00 - 15:20 **Cell therapy with CAR T cells**  
C. June, University of Pennsylvania- Clinical Research Building, Philadelphia, US

15:20 - 15:40 **Cell therapy with TCR-engineered T cells**

15:40 - 16:00 **Novel tools to investigate safety and efficacy for T cell therapy**  
S. Reker Hadrup, National Veterinary Institute (DTU Vet), Copenhagen, DK

16:00 - 16:10 **Q&A**

**16:40 - 18:10** **Type: Educational session** **Room A**  
**Title: Metabolism and metabolomics**  
Moderation: Pedro Romero, CH; Luciana Berod, DE

16:40 - 17:00 **What intratumoural tregs eat makes them strong and vulnerable**  
P.-C. Ho, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH

17:00 - 17:20 **Metabolic guidance to T cell memory formation**  
L. Berod, Twincore - Institute of Infection Immunology, Hannover, DE

17:20 - 17:40 **T cell responses in a hypoxic microenvironment**  
I. Foskolou, University of Cambridge, Cambridge, GB

17:40 - 18:00 **Obesity and anti-obesity interventions on immune-cell mediated anti-tumor responses**

18:00 - 18:10 **Q&A**

**16:40 - 18:10**    **Type: Educational session**    **Room C**  
**Title: New vaccine technologies and administration modalities**

16:40 - 17:00    **How to best predict neoantigens for personalized anti-tumour vaccines?**  
R. Yelenksy, Gritstone Oncology, Emeryville, US

17:00 - 17:20    **Addressing heterogeneity - a hot topic**  
O. Rekdal, Lytix Biopharma, Oslo, NO

17:20 - 17:40    **Intra-tumor immunotherapy**  
T. De Baere, Institut Gustave Roussy, Villejuif, FR

17:40 - 18:00    **Boosting antigen presentation in the tumor: TLR agonists & FLT3 ligand**  
J. Brody, Mount Sinai Hospital, New York City, US

18:00 - 18:10    **Q&A**

12.12.2019

**08:45 - 10:15**    **Type: Proffered Paper session**    **Room A**  
**Title: Proffered Paper session**

**08:45 - 10:15**    **Type: Educational session**    **Room C**  
**Title: Diverse functions of innate immune cells in cancer**  
Moderation: Karin de Visser, NL

08:45 - 09:05    **Exploring and exploiting the tumor microenvironment**  
J. Joyce, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Lausanne, CH

09:05 - 09:25    **NK cells and their check points**  
E. Vivier, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

09:25 - 09:45    **The IL-8 neutrophil collusion against cancer immunotherapy**  
I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

09:45 - 10:05    **How the genetic makeup of cancer dictates the immune landscape**  
K. De Visser, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:05 - 10:15    **Q&A**

**10:15 - 10:45**    **Type: Coffee break**    **Foyer**  
**Title: Coffee break**

**10:45 - 12:15**    **Type: Educational session**    **Room A**  
**Title: Tumour microenvironment and immune cells**  
Moderation: Stefani Spranger, US; Johanna Joyce, CH

10:45 - 11:05    **Immunomodulation in embryogenesis and cancer**  
J. Seoane, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

11:05 - 11:25    **Targeting macrophages in glioma**  
L. Akkari, The Netherlands Cancer Institute, Amsterdam, NL

11:25 - 11:45    **Impact of tumor-resident dendritic cells on anti-tumor T cell responses**  
S. Spranger, Koch Institute For Integrative Cancer Research at MIT, Cambridge, US

11:45 - 12:05    **The role of tumor-residing neutrophils in shaping anti-tumor immunity**  
V. Bronte, Ospedale Universitario Verona, Verona, IT

12:05 - 12:15    **Q&A**

<b>10:45 - 11:45</b>	<b>Type: Mini Oral session</b> <b>Title: Mini Oral session</b>	<b>Room C</b>
<b>12:15 - 13:15</b>	<b>Type: Poster Display session</b> <b>Title: Lunch &amp; Poster Display session</b>	<b>Room B</b>
<b>13:15 - 14:15</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry Satellite Symposium 2</b>	<b>Room C</b>
<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Chest tumours: Updates</b> Moderation: Natasha Leighl, CA; Alessandra Curioni, CH	<b>Room A</b>

14:30 - 14:50	<b>First line treatment of advanced NSCLC with no targetable alterations</b> <u>E. Garon</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, US
14:50 - 15:10	<b>Neoadjuvant treatment of NSCLC with immunotherapy: Where are we now?</b> <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH
15:10 - 15:30	<b>Immunotherapy in SCLC: First and second-line approaches</b> <u>N. Leighl</u> , Princess Margaret Cancer Center, Toronto, CA
15:30 - 15:50	<b>Immunotherapy for mesothelioma: What's new?</b> <u>S. Popat</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB
15:50 - 16:00	<b>Q&amp;A</b>

<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Gastrointestinal cancers: Updates</b> Moderation: Josep Tabernero, ES	<b>Room C</b>
14:30 - 14:50	<b>Consensus on MSI/MMR determination to select patients eligible for anti-PD1 therapies</b> <u>A. Scarpa</u> , AOU Integrata Borgo Roma Verona, Verona, IT	
14:50 - 15:10	<b>Immune therapeutics in gastroesophageal cancer</b> <u>J. Tabernero</u> , Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES	
15:10 - 15:20	<b>Immune therapeutics in HCC</b> <u>B. Sangro</u> , Clinica Universidad de Navarra, Pamplona, ES	
15:20 - 15:40	<b>Immune therapeutics in CRC (MSI and experimental approaches in MSS tumours)</b> <u>M. Chalabi</u> , Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL	
15:40 - 16:00	<b>Q&amp;A</b>	
<b>16:00 - 16:30</b>	<b>Type: Coffee break</b> <b>Title: Coffee break</b>	<b>Foyer</b>

**16:30 - 18:00**    **Type: Educational session**    **Room A**  
**Title: Skin cancers: Updates**  
Moderation: Caroline Robert, FR

- 16:30 - 16:50    **Neoadjuvant immunotherapy for melanoma**  
C. Blank, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 16:50 - 17:10    **Beyond immune checkpoint inhibitors**  
A. Eggermont, Institut Gustave Roussy, Villejuif, FR
- 17:10 - 17:30    **Combination or sequence of immunotherapy and targeted therapy, update**  
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 17:30 - 17:50    **New treatment approaches in advanced cSCC**  
D. Schadendorf, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 17:50 - 18:00    **Q&A**

**16:30 - 18:00**    **Type: Educational session**    **Room C**  
**Title: Imaging and nuclear medicine**

- 16:30 - 16:50    **Engineered immune cells as highly sensitive cancer diagnostics**  
A. Mayer, Stanford University School of Medicine, Stanford, US
- 16:50 - 17:10    **Radiomics approach in relation to immunotherapy**  
R. Sun, Institut Gustave Roussy, Villejuif, FR
- 17:10 - 17:30    **PET imaging to visualize immunotherapy**  
E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL
- 17:30 - 17:50    **Role innovative imaging in immunotherapy**  
D. De Ruyscher, Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL
- 17:50 - 18:00    **General discussion / Q&A**

**18:15 - 19:15**    **Type: Industry Satellite Symposium**    **Room C**  
**Title: Industry Satellite Symposium 3**



13.12.2019

**08:00 - 09:00**    **Type: Collaborative**    **Room**  
**Title: ESMO-CIRSE Collaborative session: Interventional oncology and**    **A**  
**immuno-oncology**

08:00 - 08:05    **Introduction**

T. De Baere, Institut Gustave Roussy, Villejuif, FR

08:05 - 08:17    **Locoregional delivery of immunotherapy**

L. Tselikas, Institut Gustave Roussy, Villejuif, FR

08:17 - 08:29    **Percutaneous ablation to stimulate tumor immunity**

B. Aarts, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:29 - 08:41    **Intra-arterial therapies and immune response**

R. Duran, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

08:41 - 08:53    **Intra-Tumoral RECIST: The complexity of non-enestic response**

L. Schwartz, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

08:53 - 08:58    **Conclusions and perspectives**

**08:00 - 09:00**    **Type: Mini Oral session**    **Room C**  
**Title: Mini Oral session**

**09:10 - 10:40**    **Type: Educational session**    **Room A**  
**Title: Innovative technological development**

09:10 - 09:30    **Artificial intelligence for digital tissue biomarker discovery in immune oncology**  
G. Schmidt, Definiens AG, Munich, DE

09:30 - 09:50    **Development and commercialisation of a first-in-class chimeric antigen receptor T cell product for large cell lymphoma**  
A. Bot, KITE Pharma, Inc, Santa Monica, US

09:50 - 10:10    **RNA vaccines**  
Ö. Türeci, BioNTech AG, Mainz, DE

10:10 - 10:30    **Capped antibody platform**  
M. Will, CytomX Therapeutics, South San Francisco, US

10:30 - 10:50    **Q&A**

**09:10 - 10:40**    **Type: Educational session**    **Room C**  
**Title: Genitourinary cancers: Updates**  
Moderation: Thomas Powles, GB; Cristina Suarez Rodriguez, ES

09:10 - 09:30    **Combinations in front line renal cancer**  
C. Suarez Rodriguez, Vall d'Hebron University Hospital, Barcelona, ES

09:30 - 09:50    **Immune therapy for prostate cancer**  
R. Jones, Beatson West of Scotland Cancer Centre, Glasgow, GB

09:50 - 10:10    **Bladder cancer: New treatments and new biomarkers**  
T. Powles, St. Bartholomew's Hospital, London, GB

10:10 - 10:30    **Immune therapy in non-metastatic bladder cancer**  
M. Van Der Heijden, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL

10:30 - 10:40    **Q&A**

**10:40 - 11:00**    **Type: Coffee break**    **Foyer**  
**Title: Coffee break**

**11:00 - 12:30**    **Type: Educational session**    **Room A**  
**Title: Novel biomarkers and drugs**

11:00 - 11:20    **Novel engineered immune agonists for cancer immunotherapy**

P. Umana, Roche Glycart AG - Switzerland, Schlieren, CH

11:20 - 11:40    **Imaging mass cytometry to characterize the tumor immune microenvironment**

M.P. Serra, AstraZeneca, Cambridge, GB

11:40 - 12:00    **Biomarkers in the era of combination therapies: Complexities and potential solutions**

Z.A. Cao, Merck Sharp & Dohme Corp. USA, Whitehouse Station, US

12:00 - 12:20    **Genomic biomarkers for immunotherapy in cancer**

P. Febbo, Genomic Health, Inc., Redwood City, US

**11:00 - 12:30**    **Type: Proffered Paper session**    **Room C**  
**Title: Proffered Paper session**

**12:30 - 13:15**    **Type: Coffee break**    **Foyer**  
**Title: Lunch**

**13:15 - 14:15**    **Type: Industry Satellite Symposium**    **Room C**  
**Title: Industry Satellite Symposium 4**

**14:30 - 16:00**    **Type: Educational session**    **Room A**  
**Title: Artificial intelligence (AI) meets immuno-oncology**  
Moderation: Thomas Powles, GB; Pedro Romero, CH

14:30 - 14:50    **AI assisted-integrative view of the tumor microenvironment**

T. Gajewski, The University of Chicago, Chicago, US

14:50 - 15:10    **Genomics correlates of response to immunotherapy**

N. Vokes, Dana Farber Cancer Institute, Boston, US

15:10 - 15:30    **Computational biology of antigen processing and presentation: A key to personalised immunotherapy of cancer**

D. Gfeller, Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH

15:30 - 15:50    **AI in radiomics**

Z. Bodalal, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:50 - 16:00    **General discussion / Q&A**

<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Haematological malignancies: Updates</b> Moderation: Judith Anne Shizuru, US	<b>Room C</b>
14:30 - 14:50	<b>Lecture title TBD</b>	
14:50 - 15:10	<b>Engineered mAbs in haem malignancies</b> <u>H. Salih</u> , German Cancer Consortium, Tübingen, DE	
15:10 - 15:30	<b>Academic development of CAR CIK-cells in B-cell neoplasia</b> <u>A. Biondi</u> , Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT	
15:30 - 15:50	<b>Precision hematopoietic stem cell replacement therapy</b> <u>J.A. Shizuru</u> , Stanford University School of Medicine, Stanford, US	
<b>16:00 - 16:30</b>	<b>Type: Coffee break</b> <b>Title: Coffee break</b>	<b>Foyer</b>
<b>16:30 - 18:00</b>	<b>Type: Educational session</b> <b>Title: Breast and gynaecological cancers: Updates</b> Moderation: Marleen Kok, NL; Lana Kandalaft, CH	<b>Room A</b>
16:30 - 16:50	<b>Defining the immunogram of breast cancer: Evidences from the neoadjuvant trials</b> <u>M. Kok</u> , Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL	
16:50 - 17:10	<b>Immunotherapy landscape in metastatic breast cancer</b> <u>G. Curigliano</u> , Istituto Europeo di Oncologia, Milan, IT	
17:10 - 17:30	<b>Personalised cancer vaccines in ovarian cancer</b> <u>L. Kandalaft</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
17:30 - 17:50	<b>Combining PARP inhibition and immunotherapy in ovarian cancer</b> <u>P. Konstantinopoulos</u> , Dana-Farber Cancer Institute, Boston, US	
17:50 - 18:00	<b>Q&amp;A</b>	

**16:30 - 18:00**    **Type: Educational session**    **Room C**  
**Title: Head & neck cancers: Updates**

16:30 - 16:50    **Update on current state of immune checkpoint inhibitors in H&N cancer**  
A. Chan, Prince of Wales Hospital, Shatin, HK

16:50 - 17:10    **Oncolytic virus therapies for head and neck cancer**  
K. Harrington, Institute of Cancer Research ICR, London, GB

17:10 - 17:30    **Toll-like receptor agonists and other innate immune activators in H&N cancer**  
E. Cohen, The University of Chicago Medical Centre, Chicago, US

17:30 - 17:50    **Radiation-mediated activation of immune responses in H&N cancer**  
E. Deutsch, Institut Gustave Roussy, Villejuif, FR

17:50 - 18:00    **Q&A**

14.12.2019

**09:00 - 10:30** **Type: Educational session** **Room**  
**Title: On the cross-talk endothelial cells: Immune cells in the tumor** **A**  
**microenvironment**

09:00 - 09:20 **Desmoplastic colorectal carcinoma**

T. Petrova, UNIL - University of Lausanne, Lausanne, CH

09:20 - 09:40 **Lymphatic endothelial cells as antigen presenting cells in tumor T cell immunity**

S. Hugues, Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH

09:40 - 10:00 **Inducing high endothelial venules in cancer to enhance immunotherapy**

G. Bergers, VIB - Center for Cancer Biology, Leuven, BE

10:00 - 10:20 **Combining antiangiogenic and immune checkpoint blockade**

J. Bedke, University of Tuebingen, Tübingen, DE

10:20 - 10:30 **General discussion / Q&A**

**09:00 - 10:30** **Type: Educational session** **Room C**  
**Title: Brain tumours: Updates**  
Moderation: Michael Weller, CH

09:00 - 09:20 **Biomarkers of response to checkpoint inhibition in glioblastoma**

E. Franceschi, Ospedale Bellaria, Bologna, IT

09:20 - 09:40 **Immune checkpoint inhibition for glioblastoma: Update on the first three CheckMate trials**

M. Weller, Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH

09:40 - 10:00 **Peptide based vaccination therapy for glioblastoma**

P.-Y. Dietrich, Hôpitaux Universitaires de Genève - HUG, Geneva, CH

10:00 - 10:20 **Immune checkpoint inhibition for patients with brain metastasis: Patient selection and assessment of benefit**

E. Le Rhun, Roger Salengro Hospital, Lille, FR

10:20 - 10:30 **Q&A**

**10:30 - 11:00** **Type: Coffee break** **Foyer**  
**Title: Coffee break**

**11:00 - 12:30** **Type: Educational session** **Room A**  
**Title: Tumour antigens and neoantigens**

Moderation: Andrew Furness, GB; George Coukos, CH

11:00 - 11:20 **State of the art: Neoantigens, T cell recognition and tumour rejection**

Y. Samuels, Weizmann Institute of Science, Rehovot, IL

11:20 - 11:40 **Beyond high TMB: Neoantigen landscape in ovarian cancer**

G. Coukos, Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH

11:40 - 12:00 **Immunoediting: Anti-tumour immunity and tumour evolution**

R. Rosenthal, UCL - University College London, London, GB

12:00 - 12:20 **Translation: Clinical application of neoantigen-reactive T cells**

A. Gros, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

12:20 - 12:30 **Q&A**

**11:00 - 12:30** **Type: Educational session** **Room C**  
**Title: Reducing costs by decreasing either dose or frequency of dosing**

Moderation: Daniel Goldstein, IL

11:00 - 11:20 **Opportunities to reduce dosing frequency of checkpoint inhibitors**

D. Goldstein, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL

11:20 - 11:40 **Pharmacokinetic modelling and therapeutic drug monitoring**

11:40 - 12:00 **Dose Reductions from the perspective of the health care payer**

12:00 - 12:20 **Dosing reductions of checkpoint inhibitors in lung cancer**

**12:40 - 13:15** **Type: Coffee break** **Foyer**  
**Title: Light lunch**